QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.108.136309v1 325/2/588    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Fricks, I. P. Articles by Harden, T. K. PubMed PubMed Citation Articles by Fricks, I. P. Articles by Harden, T. K.

CELLULAR AND MOLECULAR

UDP Is a Competitive Antagonist at the Human P2Y₁₄ Receptor

Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (I.P.F., S.M., R.C., E.R.L., R.A.N., T.K.H.); and Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland (K.A.J.)

G protein-coupled P2Y receptors (P2Y-R) are activated by adenine and uracil nucleotides. The P2Y₁₄ receptor (P2Y₁₄-R) is activated by at least four naturally occurring UDP sugars, with UDP-glucose (UDP-Glc) being the most potent agonist. With the goal of identifying a competitive antagonist for the P2Y₁₄-R, UDP was examined for antagonist activity in COS-7 cells transiently expressing the human P2Y₁₄-R and a chimeric G protein that couples Gi-coupled receptors to stimulation of phosphoinositide hydrolysis. UDP antagonized the agonist action of UDP-Glc, and Schild analysis confirmed that the antagonism was competitive (pK_B = 7.28). Uridine 5'-O-thiodiphosphate also antagonized the human P2Y₁₄-R (hP2Y₁₄-R) with an apparent affinity similar to that of UDP. In contrast, no antagonist activity was observed with ADP, CDP, or GDP, and other uracil analogs also failed to exhibit antagonist activity. The antagonist activity of UDP was not observed at other hP2Y-R. In contrast to its antagonist action at the hP2Y₁₄-R, UDP was a potent agonist (EC₅₀ = 0.35 µM) at the rat P2Y₁₄-R. These results identify the first competitive antagonist of the P2Y₁₄-R and demonstrate pharmacological differences between receptor orthologs.

Address correspondence to: Dr. T. Kendall Harden, Department of Pharmacology, University of North Carolina, CB#7365 Mary Ellen Jones Bldg., Chapel Hill, NC 27599-7365. E-mail: tkh{at}med.unc.edu